GeoVax to Present COVID-19 Vaccine Data for Immunocompromised Patients at European Vaccine Congress

GeoVax Labs, Inc. announced that members of its executive medical and scientific team will deliver presentations at the upcoming World Vaccine Congress Europe 2025, highlighting interim safety data and special-populations insights for its GEO-CM04S1 COVID-19 vaccine in immunocompromised patients. The conference, scheduled for October 13–16, 2025, at the RAI Amsterdam Convention Centre, brings together global experts across vaccine science, clinical development, manufacturing, and public health. More details about the event can be found at https://worldvaccinecongress.com/europe.

Mark J. Newman, PhD, GeoVax Chief Scientific Officer, will participate in the Special Populations Workshop during the Pre-Congress Workshops on Monday, October 13. His presentation, titled "Vaccine design to address the immunocompromised: T-lymphocyte driven…Balanced immunity - Broader specificity - Increased memory," will focus on vaccine development challenges for vulnerable populations, including those with compromised immune systems. This workshop aims to address the urgent need for more effective vaccine options in these patient groups where current authorized COVID-19 vaccines have shown limitations.

Kelly T. McKee, Jr., MD, MPH, GeoVax Chief Medical Officer, will present a scientific poster titled "Interim Safety and Reactogenicity of GEO-CM04S1, an MVA-vectored, multi-antigen COVID-19 vaccine, in adults with hematologic malignancies receiving cellular therapies." The poster, highlighting the safety profile of GEO-CM04S1 in this important target population, will be on display in the Poster Zone from October 14–16. This data represents significant progress in developing vaccines specifically tailored for patients with blood cancers and other immunocompromising conditions.

David Dodd, GeoVax President & CEO, emphasized the importance of this international gathering, stating that the company looks forward to highlighting progress with its multi-antigen GEO-CM04S1 in immunocompromised populations where the need for more effective vaccine options remains urgent. The World Vaccine Congress Europe is recognized as one of the most important international gatherings in vaccine research, development and policy, providing a platform for sharing critical advancements in global health.

GEO-CM04S1 represents a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. These trials evaluate the vaccine as a primary option for immunocompromised patients, including those with hematologic cancers, as a booster vaccine in patients with chronic lymphocytic leukemia, and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines. The company's strong IP portfolio supports its technologies and product candidates, with worldwide rights for its technologies and products. Additional information about the company's clinical trials and updates is available at https://www.geovax.com.

The presentations at the World Vaccine Congress Europe come at a critical time when vaccine development for special populations remains a global health priority. Immunocompromised patients, particularly those with hematologic malignancies, have demonstrated reduced responses to current COVID-19 vaccines, creating an urgent need for more effective alternatives. The interim safety data being presented could have significant implications for future vaccine development strategies and public health policies targeting vulnerable populations worldwide.